Healthleap raised $38 million to expand its hospital AI platform, which analyzes records to flag patients who may need clinical review.
Healthleap has raised $38 million in seed and Series A funding to grow an AI platform that scans hospital records for signs of potentially overlooked conditions. The October 7 report from TechCrunch says the financing comprises an $8 million seed round co-led by Sequoia Capital and First Round Capital, followed by a $30 million Series A led by Hummingbird Ventures. The company did not disclose its valuation.
The platform connects to electronic health record systems and analyzes both structured information—such as laboratory results and vital signs—and clinicians’ written notes. Language models help extract references to clinical concepts, including weight loss, poor appetite and difficulty swallowing. The system combines those signals with other patient data to identify people who may warrant a closer look by care teams. Healthleap says its software flags risk for review; it does not diagnose patients.
The company says the platform is deployed in more than 50 hospitals and currently screens for issues including malnutrition and delirium. Other programs, covering conditions such as aspiration pneumonia, pressure ulcers and readmission risk for congestive heart failure, are undergoing further clinical validation. Healthleap says its customers include Penn Medicine, Cedars-Sinai, Intermountain, Houston Methodist and Emory Healthcare.
The funding offers a view into how healthcare AI companies are trying to address gaps in routine care without positioning a model as a replacement for clinicians. Hospitals already hold large volumes of patient data, but important details can be buried in narrative notes or missed amid competing demands. Surfacing those details inside existing workflows may help care teams prioritize follow-up, though the value depends on reliable signals, clinician adoption and appropriate validation.
Healthleap plans to use the capital for engineering, product development, sales and customer support as it adds conditions and explores outpatient and home-care settings. The company has described strong growth and customer-reported financial returns, but those figures are company claims cited in the report, not independent proof of clinical benefit. Broader expansion will require evidence that alerts are accurate and useful across different patient populations and health systems.